Free Trial

ASR Vermogensbeheer N.V. Takes Position in DexCom, Inc. (NASDAQ:DXCM)

DexCom logo with Medical background

Key Points

  • ASR Vermogensbeheer N.V. acquired 24,919 shares of DexCom, Inc. valued at approximately $1.7 million during Q1, according to a recent SEC filing.
  • Several institutional investors increased their stakes in DexCom, leading to a total institutional ownership of 97.75%.
  • DexCom reported a strong earnings performance, beating analysts' estimates with $0.48 EPS and a year-over-year revenue increase of 15.2%.
  • Need better tools to track DexCom? Try 5 Weeks of MarketBeat All Access for $5. Start Portfolio Tracking Now.

ASR Vermogensbeheer N.V. bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The fund bought 24,919 shares of the medical device company's stock, valued at approximately $1,702,000.

Several other hedge funds have also recently made changes to their positions in DXCM. Vanguard Group Inc. grew its position in DexCom by 2.0% during the 1st quarter. Vanguard Group Inc. now owns 47,455,899 shares of the medical device company's stock worth $3,240,763,000 after purchasing an additional 925,882 shares during the period. Intrust Bank NA purchased a new position in DexCom in the 1st quarter worth approximately $270,000. Ithaka Group LLC lifted its stake in DexCom by 0.4% in the 1st quarter. Ithaka Group LLC now owns 109,670 shares of the medical device company's stock worth $7,489,000 after purchasing an additional 448 shares in the last quarter. Westfield Capital Management Co. LP raised its position in shares of DexCom by 4.4% during the 1st quarter. Westfield Capital Management Co. LP now owns 2,447,743 shares of the medical device company's stock valued at $167,156,000 after buying an additional 102,142 shares during the period. Finally, Geneva Capital Management LLC raised its position in shares of DexCom by 4.5% during the 1st quarter. Geneva Capital Management LLC now owns 118,072 shares of the medical device company's stock valued at $8,063,000 after buying an additional 5,095 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Trading Down 1.3%

NASDAQ DXCM traded down $1.01 during trading on Monday, reaching $77.85. 4,224,176 shares of the stock traded hands, compared to its average volume of 3,920,515. The firm has a market cap of $30.53 billion, a price-to-earnings ratio of 54.06, a price-to-earnings-growth ratio of 1.65 and a beta of 1.43. The stock's 50-day moving average price is $83.53 and its 200 day moving average price is $80.20. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $93.25.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, topping analysts' consensus estimates of $0.45 by $0.03. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The firm's revenue for the quarter was up 15.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.43 earnings per share. Analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

Analysts Set New Price Targets

DXCM has been the subject of several research reports. UBS Group boosted their price target on shares of DexCom from $105.00 to $106.00 and gave the stock a "buy" rating in a research note on Thursday, July 31st. Mizuho raised their price objective on DexCom from $95.00 to $100.00 and gave the stock an "outperform" rating in a report on Wednesday, July 16th. Canaccord Genuity Group reissued a "buy" rating and set a $106.00 price target on shares of DexCom in a report on Friday, August 1st. Citigroup reissued a "buy" rating and set a $102.00 price target (up previously from $82.00) on shares of DexCom in a report on Thursday, May 22nd. Finally, Robert W. Baird lowered their price objective on DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. Four research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $99.89.

Get Our Latest Stock Report on DexCom

Insider Activity at DexCom

In related news, EVP Michael Jon Brown sold 10,000 shares of the firm's stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $84.28, for a total value of $842,800.00. Following the completion of the transaction, the executive vice president owned 95,602 shares in the company, valued at $8,057,336.56. This trade represents a 9.47% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Nicholas Augustinos sold 3,672 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $82.80, for a total transaction of $304,041.60. Following the transaction, the director owned 33,411 shares of the company's stock, valued at approximately $2,766,430.80. The trade was a 9.90% decrease in their position. The disclosure for this sale can be found here. Insiders sold 28,656 shares of company stock valued at $2,412,191 over the last three months. Company insiders own 0.32% of the company's stock.

DexCom Company Profile

(Free Report)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Further Reading

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Should You Invest $1,000 in DexCom Right Now?

Before you consider DexCom, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DexCom wasn't on the list.

While DexCom currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Growth Stocks That Could Pop Before Summer Ends
3 Buy-the-Dip Stocks Poised to Rebound Soon
Quantum Boom: 3 Strong Picks with Lower Risk

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines